

## EU DECLARATION OF CONFORMITY (DoC)



<b>Manufacturer:</b>	Becton, Dickinson and Company BD Biosciences 155 North McCarthy Boulevard Milpitas, California 95035 USA																		
<b>Manufacturer SRN:</b>	US-MF-000017797																		
<b>Authorised Representative:</b>	Becton Dickinson Ireland Ltd. Donore Road, Drogheda Co. Louth, A92 YW26 Ireland																		
<b>Authorised Representative SRN:</b>	IE-AR-000007610																		
<b>Product:</b>	<table> <tr> <td>BD® Anti-HLA-DR (L243) FITC</td><td><b>REF</b> 347400</td></tr> <tr> <td>BD® Anti-HLA-DR (L243) PE</td><td><b>REF</b> 347401</td></tr> <tr> <td>BD® Anti-HLA-DR (L243) PerCP</td><td><b>REF</b> 347402</td></tr> <tr> <td>BD® Anti-HLA-DR (L243) PerCP-Cy5.5</td><td><b>REF</b> 339216</td></tr> <tr> <td>BD® Anti-HLA-DR (L243) PE-Cy7</td><td><b>REF</b> 335830</td></tr> <tr> <td>BD® Anti-HLA-DR (L243) APC</td><td><b>REF</b> 347403</td></tr> <tr> <td>BD® Anti-HLA-DR (L243) APC-Cy7</td><td><b>REF</b> 335831</td></tr> <tr> <td>BD® Anti-HLA-DR (L243) APC-H7</td><td><b>REF</b> 641411</td></tr> <tr> <td>BD® Anti-HLA-DR (L243) V450</td><td><b>REF</b> 655874</td></tr> </table>	BD® Anti-HLA-DR (L243) FITC	<b>REF</b> 347400	BD® Anti-HLA-DR (L243) PE	<b>REF</b> 347401	BD® Anti-HLA-DR (L243) PerCP	<b>REF</b> 347402	BD® Anti-HLA-DR (L243) PerCP-Cy5.5	<b>REF</b> 339216	BD® Anti-HLA-DR (L243) PE-Cy7	<b>REF</b> 335830	BD® Anti-HLA-DR (L243) APC	<b>REF</b> 347403	BD® Anti-HLA-DR (L243) APC-Cy7	<b>REF</b> 335831	BD® Anti-HLA-DR (L243) APC-H7	<b>REF</b> 641411	BD® Anti-HLA-DR (L243) V450	<b>REF</b> 655874
BD® Anti-HLA-DR (L243) FITC	<b>REF</b> 347400																		
BD® Anti-HLA-DR (L243) PE	<b>REF</b> 347401																		
BD® Anti-HLA-DR (L243) PerCP	<b>REF</b> 347402																		
BD® Anti-HLA-DR (L243) PerCP-Cy5.5	<b>REF</b> 339216																		
BD® Anti-HLA-DR (L243) PE-Cy7	<b>REF</b> 335830																		
BD® Anti-HLA-DR (L243) APC	<b>REF</b> 347403																		
BD® Anti-HLA-DR (L243) APC-Cy7	<b>REF</b> 335831																		
BD® Anti-HLA-DR (L243) APC-H7	<b>REF</b> 641411																		
BD® Anti-HLA-DR (L243) V450	<b>REF</b> 655874																		
<b>Basic UDI-DI:</b>	038290WGOEVGIDG8																		
<b>Risk Class and Rule:</b>	Class C, Annex VIII, Rule 3(g) & Rule 3(h)																		
<b>Intended Purpose:</b>	<p>Anti-HLA-DR (L243) is intended for in vitro diagnostic use in the identification of cells expressing the HLA-DR antigen in peripheral blood, using a BD FACSLyric™ flow cytometer.</p> <p><u>Clinical Applications</u></p> <p>Expression of the HLA-DR antigen in the characterization of subjects having, or suspected of having, hematological neoplasia.</p> <p>Anti-HLA-DR (L243) is a qualitative reagent intended for laboratory professional use only.</p>																		
<b>Notified Body:</b>	BSI Group The Netherlands B.V. Say Building, John M. Keynesplein 9, 1066 EP Amsterdam, Netherlands Notified Body Number: 2797																		
<p>We, as the manufacturer of the device(s) take sole responsibility for and hereby declare that the above-mentioned product(s) meet(s) the provisions of the following Directives/ Regulation(s):</p> <ul style="list-style-type: none"> <li>Regulation (EU) 2017/746 on In vitro Diagnostic Medical Devices.</li> </ul>																			

## Conformity Assessment Route:

<input type="checkbox"/> ANNEX IX Technical File Examination	EC CERTIFICATE No.: EC Certificate Expiration Date:
<input checked="" type="checkbox"/> ANNEX IX Full Quality System	EC CERTIFICATE No.: 728780 R000 EC Certificate Expiration Date: 2025-December-16
<input type="checkbox"/> ANNEX X Type Examination	EC CERTIFICATE No.: EC Certificate Expiration Date:
<input type="checkbox"/> ANNEX XI Production Quality System	EC CERTIFICATE No.: EC Certificate Expiration Date:
<input type="checkbox"/> ANNEX I & II+III	N/A

## Common Specifications (CS):

Common Specifications have not been issued for this product.

Authorised Signatory:	
<b>Name &amp; Title:</b>	Mirna Dipano, Vice President, Regulatory Affairs
<b>On behalf of:</b>	Becton, Dickinson and Company BD Biosciences 155 North McCarthy Boulevard Milpitas, California 95035 USA
<b>Place of Issue:</b>	Milpitas, California USA
<b>Date of Issue:</b>	Please refer to Signature section.
<b>Signature:</b>	<div>  <p>DocuSigned by: Mirna Dipano</p> <p> Signer Name: Mirna Dipano Signing Reason: I approve this document Signing Time: 03-Jul-2023   10:45:50 AM PDT 6166B70768DA44C1A0CA7A9871E2F40A</p> </div>

## DECLARATION OF CONFORMITY Revision History:

Version:	Detailed Change Description:
A	Original release.
B	Update to Corporate Template CBI-058 FRM24 Revision 04. Updated Risk Class & Rule section by replacing “Class C, Annex VIII Rule 3” with “Class C, Annex VIII, Rule 3(g) & Rule 3(h)” to support global registration, and removed the Template Revision History section. Included the detailed address of the Notified Body. Updated the Date of Issue section in the Authorised Signatory table from date generated from DocuSign to “Please refer to Signature section.”
C	Updated grammar and formatting. Updated the legal manufacturer address and PRRC.